Citations

Clear

590 citation(s) found for "Ho, Ben".

Conventional Platinum Metal Implants Provoke Restenosis Responses in Atherogenic but Not Healthy Arteries
Morath, Lea M. , Oliver, Alexander A , Liu, Shu Q. , Bocks, Martin L. , Levy, Galit Katarivas , Goldman, Jeremy , Oliver, Alexander A , Guillory, Roger J. , Drelich, Jaroslaw Wieslaw

Mayo Clinic

Sci | June 20, 2023 | Volume: 5 | Issue: 2 | Pages: 25

10.3390/sci5020025 Get It

Platinum-containing stents are commonly used in humans with hypercholesterolemia, whereas preclinical stent evaluation has commonly been performed in healthy animal models, providing inadequate information about stent performance under hypercholesterolemic conditions. In this investigation, we used an ApoE−/− mouse model to test the impact of hypercholesterolemia on neointima formation on platinum-containing implants. We implanted 125 μm diameter platinum wires into the abdominal aortas of ApoE−/− and ApoE+/+ mice for 6 months, followed by histological and immunofluorescence examination of neointimal size and composition. It was found that ApoE−/− mice developed neointimas with four times larger area and ten times greater thickness than ApoE+/+ counterparts. Neointimas developed in the ApoE−/− mice also contained higher amounts of lipids quantified as having 370 times more coverage compared to ApoE+/+, a 3-fold increase in SMCs, and a 22-fold increase in macrophages. A confluent endothelium had regenerated in both mouse strains. The ApoE−/− mice experienced luminal reductions more closely resembling clinically relevant restenosis in humans. Overall, the response to platinum arterial implants was highly dependent upon the atherogenic environment.
Erector Spinae Plane (ESP) Block for Postoperative Pain Management after Open Oncologic Abdominal Surgery
Dubilеt, Michael , Gruenbaum, Benjamin F. , Semyonov, Michael, Ishay, Shlomo Yaron, Osyntsov, Anton , Friger, Michael , Geftler, Alexander , Brotfain, Evgeni , Brotfain, Evgeni , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

Pain Research and Management | June 16, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-9

10.1155/2023/9010753 | PMID 37360747 Get It

Patients undergoing abdominal oncologic surgical procedures require particular surgical and anesthesiologic considerations. Traditional pain management, such as opiate treatment, continuous epidural analgesia, and non-opioid drugs, may have serious side effects in this patient population. We evaluated erector spinae plane (ESP) blocks for postoperative pain management following elective oncologic abdominal surgeries. In this single-center, prospective, and randomized study, we recruited 100 patients who underwent elective oncological abdominal surgery between December 2020 and January 2022 at Soroka University Medical Center in Beer Sheva, Israel. We compared postoperative pain levels in patients who were treated with a preincisional ESP block in addition to traditional pain management with intravenous opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and acetaminophen, compared to patients who were only given traditional pain management (control). Patients who were treated with a preincisional ESP block demonstrated significantly lower Visual Analog Scale scores at 60 minutes and 4, 8, and 12 hours following the surgery, compared to the control group ( p < 0.001 ). Accordingly, patients in the ESP group required less morphine from 60 minutes to 12 hours after surgery, but they required increased non-opioid postoperative analgesia management at 4, 8, and 12 hours after surgery ( p from 0.002 to <0.001) compared to the control group. In this study, we found ESP blocks to be a safe, technically simple, and effective treatment for postoperative pain management after elective oncologic abdominal procedures.
ATRT-15. ATRTS HIJACK EPIGENETIC MECHANISMS TO PROMOTE IMMUNOSUPPRESSION AND ESCAPE FROM NK CELL THERAPY
Swaminathan, Jyothishmathi , Ho, Ben, Maegawa, Shinji , Laureano, Álvaro Macedo , Brugmann, Ben, Kennis, Bridget, Dobson, Tara , Shaik, Shavali, Ravikumar, Visweswaran , Sandberg, David I. , Cooper, Laurence J.N. , Zaky, Wafik , Khatua, Soumen , Rao, Arvind , Harmanci, Arif , Gopalakrishnan, Vidya , Guo, Lei Ming , Silla, Lúcia Mariano da Rocha , Lee, Dean Anthony , Xu, Lin , Huang, Annie

Mayo Clinic

Neuro-Oncology | June 12, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: i4-i4

10.1093/neuonc/noad073.015 Get It

Abstract Atypical Teratoid/Rhabdoid Tumors (ATRTs) are malignant tumors of the central nervous system in children. They are almost universally characterized by genetic loss of SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin Subfamily member B1 (SMARCB1) - a core subunit of the ATP-dependent SWI/SNF chromatin remodeling complex, and dysregulation of lineage restricted enhancers. Here, we show that tumor subgroup-specific upregulation of a distant member of the transforming growth factor-β (TGF-β), bone morphogenic factor (BMF) family of proteins drives insensitivity to NK-mediated cytolysis in vitro and in vivo. Mechanistically, subgroup-specific loss of chromatin occupancy by the RE1 Silencing Transcription Factor (REST) to its consensus RE1 motif, allowed deposition of enhancer-specific histone H3 lysine4 (K4) mono-methylation and histone H3K27 acetylation marks to activate an enhancer-promoter interaction. Restoration of REST binding or BET-domain inhibition resulted in a significant reduction in the enhancer marks and enhancer-promoter interaction and involved histone H3K27me3 deposition at the REST binding site, to facilitate gene silencing and sensitization of ATRTs to NK-mediated cytolysis. Thus, our study has identified a novel function for REST as a modulator of tumor-intrinsic enhancer activity and tumor-extrinsic immune microenvironment. Of equal significance, we highlight a role of REST in recruiting the polycomb repressive complex-2 (PRC2) in gene silencing in ATRTs.
Quick Sequential Organ Failure Assessment Score Is a Better Predictor of Septic Shock After Percutaneous Nephrolithotomy: A Secondary Analysis of Two Multicenter Prospective Trials
Gerrity, Jillian J., Berger, Jonathan , Hsi, Ryan S. , Stern, Karen , Chew, Ben H. , Nimmagadda, Naren , Kavoussi, Nicholas , Chen, Tony T., Krambeck, Amy E. , Large, Tim , Bechis, Seth K. , Monga, Manoj , Miller, Nicole L. , Lange, Dirk , Knudsen, Bodo E. , Sourial, Michael , Humphreys, Mitchell R. , Shah, Ojas , Abbott, Joel E. , Abedi, Garen , Sur, Roger L. , Chew, Ben H , Nimmagadda, Naren , Knudsen, Bodo , Abedi, Garen , Stern, Karen L , Hsi, Ryan , Miller, Nicole L , Gerrity, Jillian J., Friedlander, David Fallon

Mayo Clinic

Journal of Endourology | June 9, 2023 | Volume: 37 | Issue: 8 | Pages: 863-867

10.1089/end.2022.0677 | PMID 37294208 Get It

Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study
Ben‐Joseph, Rami , Saad, Ragy , Black, Jed , Dabrowski, Elizabeth , Gallucci, Sophia, Taylor, Ben , Somers, Virend K.

Mayo Clinic

SLEEP | June 8, 2023 | Volume: 46 | Issue: 10 | Pages: No page available

10.1093/sleep/zsad161 | PMID 37305967 Get It

Abstract Study Objectives Narcolepsy is associated with cardiovascular risk factors; however, the risk of new-onset cardiovascular events in this population is unknown. This real-world study evaluated the excess risk of new-onset cardiovascular events in U.S. adults with narcolepsy. Methods A retrospective cohort study using IBM MarketScan administrative claims data (2014–2019) was conducted. A narcolepsy cohort, comprising adults (≥18 years) with at least two outpatient claims containing a narcolepsy diagnosis, of which at least one was non-diagnostic, was matched to a non-narcolepsy control cohort (1:3) based on cohort entry date, age, sex, geographic region, and insurance type. The relative risk of new-onset cardiovascular events was estimated using a multivariable Cox proportional hazards model to compute adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results The narcolepsy and matched non-narcolepsy control cohorts included 12 816 and 38 441 individuals, respectively. At baseline, cohort demographics were generally similar; however, patients with narcolepsy had more comorbidities. In adjusted analyses, the risk of new-onset cardiovascular events was higher in the narcolepsy cohort compared with the control cohort: any stroke (HR [95% CI], 1.71 [1.24, 2.34]); heart failure (1.35 [1.03, 1.76]); ischemic stroke (1.67 [1.19, 2.34]); major adverse cardiac event (1.45 [1.20, 1.74]); grouped instances of stroke, atrial fibrillation, or edema (1.48 [1.25, 1.74]); and cardiovascular disease (1.30 [1.08, 1.56]). Conclusion Individuals with narcolepsy are at increased risk of new-onset cardiovascular events compared with individuals without narcolepsy. Physicians should consider cardiovascular risk in patients with narcolepsy when weighing treatment options.
The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge: Results after 1 Year Follow-up
Bron, Esther E. , Toga, Arthur W. , Weiner, Michael W. , Barkhof, Frederik , Fox, Nick C. , Eshaghi, Arman , Toni, Tina, Salaterski, Marcin, Lunina, Veronika, Ansart, Manon , Lu, Pascal , Thompson, Wesley K., Nahon, Aviv, Levy, Yarden, Halbersberg, Dan, Cohen, Mariya, Liao, Huiling , Yu, Kaixian , Ismail, Aya, Wood, Timothy C. , Nguyen, Minh , Sun, Nanbo , Yeo, B.T. Thomas , Qi, Ke , Chen, Shiyang , Qiu, Deqiang , Buciuman, Ionut, Kelner, Alex, Rimocea, Denisa, Ourselin, Sébastien , Venkatraghavan, Vikram , Liu, Keli , Rabe, Christina, Manser, Paul T. , Howlett, James , Huang, Zhiyue , Mukherjee, Sach, Rouanet, Anaïs , Oriol, Javier de Velasco , Clemente, Edgar E. V., Estrada, Karol , Altmann, André , Stonnington, Cynthia M. , Wu, Jianfeng , Devadas, Vivek, Fourrier, Clémentine , Doshi, Jimit , Moore, Paul J. , Lyons, Terry , Ciszek, Robert, Jedynak, Bruno , Pandya, K., Engels, William R., Cole, Joseph B., Golland, Polina , Alexander, Daniel C. , Initiative, The Alzheimer's Disease Neuroimaging, Toga, Arthur W , Barkhof, Frederik , Fox, Nick C , Weiner, Michael W , Marinescu, Razvan Valentin , Oxtoby, Neil P. , Young, Alexandra L. , Durrleman, Stanley , Iddi, Samuel , Li, Dan , Donohue, Michael , Li, Tengfei , Zhu, Hongtu , Tamez‐Peña, José G. , Wood, Timothy, Bravo, Héctor Corrada , Feng, Jiashi , Chen, Gang , Qi, Ke, Pop, Raluca, Ghazi, Mostafa Mehdipour , Nielsen, Mads , Sørensen, Lauge , Hill, Steven M., Kiddle, Steven John , Taschler, Bernd , Tom, Brian D. M. , White, Simon Richard , Faux, Noel Garry , Sedai, Suman , Aksman, Leon , Wang, Yalin , Rakêt, Lars Lau , Sotiras, Aristeidis , Erus, Güray , Davatzikos, Christos , Vogel, Jacob W. , Doyle, Andrew , Tam, Angela , Diaz-Papkovich, Alex , Jammeh, Emmanuel , Koval, Igor , Gallacher, John , Tohka, Jussi , Pandya, Kruti, Bilgel, Murat , Engels, William, Cole, Joseph, Klein, Stefan , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Machine Learning for Biomedical Imaging | May 17, 2023 | Volume: 1 | Issue: December 2021 | Pages: 1-60

10.59275/j.melba.2021-2dcc Get It

Accurate prediction of progression in subjects at risk of Alzheimer's disease is crucial for enrolling the right subjects in clinical trials. However, a prospective comparison of state-of-the-art algorithms for predicting disease onset and progression is currently lacking. We present the findings of "The Alzheimer's Disease Prediction Of Longitudinal Evolution" (TADPOLE) Challenge, which compared the performance of 92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at risk of Alzheimer's disease. Challenge participants were required to make a prediction, for each month of a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer's Disease Assessment Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. The methods used by challenge participants included multivariate linear regression, machine learning methods such as support vector machines and deep neural networks, as well as disease progression models. No single submission was best at predicting all three outcomes. For clinical diagnosis and ventricle volume prediction, the best algorithms strongly outperform simple baselines in predictive ability. However, for ADAS-Cog13 no single submitted prediction method was significantly better than random guesswork. Two ensemble methods based on taking the mean and median over all predictions, obtained top scores on almost all tasks. Better than average performance at diagnosis prediction was generally associated with the additional inclusion of features from cerebrospinal fluid (CSF) samples and diffusion tensor imaging (DTI). On the other hand, better performance at ventricle volume prediction was associated with inclusion of summary statistics, such as the slope or maxima/minima of patient-specific biomarkers. On a limited, cross-sectional subset of the data emulating clinical trials, performance of the best algorithms at predicting clinical diagnosis decreased only slightly (2 percentage points) compared to the full longitudinal dataset. The submission system remains open via the website https://tadpole.grand-challenge.org, while TADPOLE SHARE (https://tadpole-share.github.io/) collates code for submissions. TADPOLE's unique results suggest that current prediction algorithms provide sufficient accuracy to exploit biomarkers related to clinical diagnosis and ventricle volume, for cohort refinement in clinical trials for Alzheimer's disease. However, results call into question the usage of cognitive test scores for patient selection and as a primary endpoint in clinical trials.
Increased Risk of Hypertension Onset Among Patients With Narcolepsy Newly Treated With High-Sodium Oxybate (P5-13.002)
Ben‐Joseph, Rami , Black, Jed , Saad, Ragy , Davis, Mat D., Macfadden, Wayne , Mues, Katherine E. , Jackson, Clark , Ni, Weiyi , Cook, Michael B. , Pitino, Julia, Latimer, Helen, Dabrowski, Elizabeth , White, William B. , Somers, Virend K. , D’Agostino, Ralph B. , Cook, Michael

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203178 Get It

Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma
Szlosarek, Peter W. , Creelan, Ben , Sarkodie, Thomas, Nolan, Luke, Olevsky, Olga, Grosso, Federica , Roy, Amy, Gilligan, David , Kindler, Hedy L. , Papadatos-Pastos, Dionysis, O’Byrne, Kenneth J. , Nowak, Anna , Steele, Jeremy, Sheaff, Michael , Johnston, Amanda , Fennell, Dean A., Taylor, Paul D. , Cortinovis, Diego Luigi , Chitnis, Meenali M. , Ceresoli, Giovanni Luca , Mansfield, Aaron S. , Tsao, Anne S. , Bomalaski, John S. , Zauderer, Marjorie G.

Mayo Clinic

Cancer Research | April 14, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: CT007-CT007

10.1158/1538-7445.am2023-ct007 Get It

Abstract Background: Arginine deprivation with ADI-PEG20 (pegargiminase) alone or combined with chemotherapy displayed antitumor activity in early phase clinical trials of argininosuccinate synthase 1 (ASS1)-deficient cancers, including pleural mesothelioma (PM). The non-epithelioid subtype of mesothelioma is particularly aggressive and arginine-auxotrophic due to frequent ASS1 loss. ATOMIC-meso is a pivotal phase 2-3 trial comparing standard of care (SOC) chemotherapy plus pegargiminase or placebo for patients (pts) with non-epithelioid PM. Methods: In this double-blind, placebo-controlled, phase 2-3 trial, we randomly assigned ECOG PS 0-1 pts with chemonaïve non-epithelioid PM in an intention-to-treat 1:1 ratio to receive q3 week SOC chemotherapy with pemetrexed (500mg/m2 i.v.) and cisplatin (75mg/m2 i.v.) with q1 week pegargiminase (36 mg/m2 i.m.) or placebo i.m. up to 6 cycles. Carboplatin (AUC5) was permitted in the phase 3 portion instead of cisplatin. Maintenance therapy with pegargiminase or placebo was continued until progression, toxicity or 24 months. The primary end point was median OS (mOS) and secondary end points included median PFS (mPFS), safety, pharmacodynamics and immunogenicity. ORR was assessed by blinded independent central review (BICR) for the phase 2 portion only using modified RECIST or RECIST v1.1. Results: 249 pts with non-epithelioid PM (median age 71, range 28-86; male 82.7%; 48.2% biphasic and 51.8% sarcomatoid) from 5 countries were randomized between Aug 2017 and Aug 2021: 125 pts were assigned to the pegargiminase-chemotherapy group and 124 pts to the placebo-chemotherapy group. The experimental arm showed a superior mOS respect to SOC: 9.3 months (95% confidence interval [CI], 7.9-11.8) vs. 7.7 months (95% CI, 6.1-9.5) (hazard ratio [HR], 0.71; 95% CI, 0.55-0.93; p=0.023). Also, the mPFS was higher in the experimental vs. control arm: 6.2 months (95% CI, 5.8-7.4) vs. 5.6 months (95% CI, 4.14-5.91) ([HR], 0.65; 95% CI, 0.46-0.90; p=0.019). The ORR by BICR was 13.8% in the pegargiminase-chemotherapy group vs. 13.5% in the placebo-chemotherapy group (p=0.95) with more stable disease in the former (71.3% vs. 62.9%). Plasma arginine declined with a reciprocal increase in citrulline. Anti-ADI-PEG20 antibodies were detected in 97.4% of patients by week 25 on pegargiminase. Grade ≥ 3 treatment-related adverse events to pegargiminase occurred in 28.8% and to placebo in 16.9%; grade ≥ 3 drug hypersensitivity and skin reactions occurred in 3.2% and 1.6% in the experimental arm, respectively, and none on placebo. Post-study drug treatment was comparable in both arms (45.6% post-pegargiminase vs. 46.8% post-placebo). Conclusions: In this first randomized trial of an arginine-depleting chemotherapy in cancer, the pegargiminase-pemetrexed-platinum triplet prolonged survival and had a favorable safety profile in pts with non-epithelioid PM (ClinicalTrials.gov Identifier NCT02709512) Citation Format: Peter W. Szlosarek, Ben Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Olga Olevsky, Federica Grosso, Diego Cortinovis, Meenali Chitnis, Amy Roy, David Gilligan, Hedy Kindler, Dionysis Papadatos-Pastos, Giovanni L. Ceresoli, Aaron Mansfield, Anne Tsao, Ken O’Byrne, Anna K. Nowak, Jeremy Steele, Michael Sheaff, Amanda Johnston, John Bomalaski, Marjorie Zauderer, Dean A. Fennell. Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT007.
The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study
Jaafari, Hussain, Houghton, Lesley A. , West, Robert , Aziz, Imran , Black, Christopher J. , Corsetti, Maura , Shuweihdi, Farag , Eugenicos, Maria , Paine, Peter , Ford, Alexander C. , Whorwell, Peter J. , Palsson, Olafur S. , Vasant, Dipesh H. , Aziz, Imran , Black, Christopher J , Corsetti, M , Ford, Alexander C , Whorwell, Peter J , Sperber, Ami D , Vasant, Dipesh H , Houghton, L A , Palsson, Olafur S , Agrawal, Anurag, Bangdiwala, Shrikant I.

Mayo Clinic

Neurogastroenterology & Motility | April 5, 2023 | Volume: 35 | Issue: 6 | Pages: No page available

10.1111/nmo.14574 | PMID 37018424 Get It

AbstractBackgroundThere are minimal epidemiological data comparing the burden of disorders of gut brain interaction (DGBI) in the UK with other countries. We compared the prevalence of DGBI in the UK with other countries that participated in the Rome Foundation Global Epidemiology Study (RFGES) online.MethodsParticipants from 26 countries completed the RFGES survey online including the Rome IV diagnostic questionnaire and an in‐depth supplemental questionnaire with questions about dietary habits. UK sociodemographic and prevalence data were compared with the other 25 countries pooled together.Key ResultsThe proportion of participants with at least one DGBI was lower in UK participants compared with in the other 25 countries (37.6% 95% CI 35.5%–39.7% vs. 41.2%; 95% CI 40.8%–41.6%,p = 0.001). The UK prevalence of 14 of 22 Rome IV DGBI, including irritable bowel syndrome (4.3%) and functional dyspepsia (6.8%), was similar to the other countries. Fecal incontinence, opioid‐induced constipation, chronic nausea and vomiting, and cannabinoid hyperemesis (p < 0.05) were more prevalent in the UK. Cyclic vomiting, functional constipation, unspecified functional bowel disorder, and proctalgia fugax (p < 0.05) were more prevalent in the other 25 countries. Diet in the UK population consisted of higher consumption of meat and milk (p < 0.001), and lower consumption of rice, fruit, eggs, tofu, pasta, vegetables/legumes, and fish (p < 0.001).Conclusions and InferencesThe prevalence and burden of DGBI is consistently high in the UK and in the rest of the world. Opioid prescribing, cultural, dietary, and lifestyle factors may contribute to differences in the prevalence of some DGBI between the UK and other countries.